Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors

Robert T. Eagan, Robert P. Dinapoli, Terrence L. Cascino, Bernd Scheithauer, Brian P. O'Neill, Judith R. O'Fallon

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Ninety-three patients with primary intracranial brain tumors recurrent after cerebral irradiation were treated with aziridinylbenzoquinone (AZQ; Diaziquone). Twenty-four (26%) had tumor regression lasting a median of 9.2 months. Prior chemotherapy was not significantly associated with tumor regression but was associated with survival (median 7.3 months no prior chemotherapy versus 4.7 months with prior chemotherapy; logrank p = 0.03). AZQ demonstrated anti-tumor activity in a wide variety of primary intracranial neoplasms recurrent after radiation therapy and deserves study in patients at the time of diagnosis. We believe alternating or combining AZQ and BCNU should be rewarding. The principal toxicity of AZQ is myelosuppression.

Original languageEnglish (US)
Pages (from-to)309-314
Number of pages6
JournalJournal of neuro-oncology
Volume5
Issue number4
DOIs
StatePublished - Dec 1 1987

Keywords

  • AZQ
  • chemotherapy
  • glioma
  • radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Comprehensive phase II evaluation of Aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human primary brain tumors'. Together they form a unique fingerprint.

  • Cite this